- 81503 - QTY (1)
Alternate Specimen Requirements
|No additive (Red)
Minimum Specimen Requirements
Mon - Sat
5 - 6 days
|Electro Chemiluminescence Immunoassay (ECLIA)
|Fixed Rate Time Nephelometry
|OVA1® Test Value
|Premenopausal: Low probability of malignancy < 5.0
|Premenopausal: High probability of malignancy >= 5.0
|Postmenopausal: Low probability of malignancy < 4.4
|Postmenopausal: High probability of malignancy >= 4.4
The OVA1® Test is an aid to further assess the likelihood that malignancy is present when the physician's independent clinical and radiological evaluation does not indicate malignancy. The OVA1® Test is a qualitative serum test that combines the results of five immunoassays into a single numerical result (Beta-2-microglobulin, CA 125II, Apolipoprotein A-1, Prealbumin, Transferrin). It is indicated for women who meet the following criteria: over age 18, ovarian adnexal mass present for which surgery is planned, and not yet referred to an oncologist. The test is not intended as a screening or stand-alone diagnostic assay, or for patients with a diagnosis of malignancy within the last 5 years, or to determine whether a patient should proceed to surgery. Samples that contain rheumatoid factor >= 250 IU/mL cannot be used in the OVA1® Test. Triglyceride levels above 4.5 g/L may interfere with the assay and should not be used in the OVA1® Test.
OVA1® Test is not to be used if patient is known to have rheumatoid factor of >= 250 IU/L. Triglycerides above 450 mg/dL may interfere with the assay and should not be used. The test is not indicated for patients with diagnosis of malignancy within the last 5 years.